CN103933277A - Tibetan drug for treating gout disease - Google Patents
Tibetan drug for treating gout disease Download PDFInfo
- Publication number
- CN103933277A CN103933277A CN201410131046.7A CN201410131046A CN103933277A CN 103933277 A CN103933277 A CN 103933277A CN 201410131046 A CN201410131046 A CN 201410131046A CN 103933277 A CN103933277 A CN 103933277A
- Authority
- CN
- China
- Prior art keywords
- tibetan medicine
- active component
- tibetan
- group
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a Tibetan drug for treating a gout disease. The Tibetan drug is prepared from an active component or an active component and pharmaceutically acceptable auxiliary materials, wherein the active component is prepared from artemisia sieversiana, herba codonopsis mollis, processed excrement of Ochotona erythrotis Buchner, mirablis himalaica and bhizoma acori calami according to a certain weight ratio. The Tibetan drug can be prepared into any one common drug for oral administration. The Tibetan drug has the functions of diminishing inflammation and relieving pain and is used for treating gout as well as redness and swelling of lower limb joints.
Description
Technical field
The present invention relates to a kind of Tibetan medicine for the treatment of goat, belong to Tibetan medicine field.
Background technology
Gout is one group, and to take hyperuricemia due to purine metabolic disturbance and/or uric acid excretion disorder be machine-processed different substantiality disease.Clinically common hyperuricemia, gouty acute arthritis repeatedly show effect, tophus deposition, characteristic chronic arthritis and joint deformity, often involve kidney and cause that chronic interstitial nephritis and kidney urate calculus form feature, are common in middle-aged male.
Gout has a lot of new knowledges in recent years to healthy significant damage, find this disease except can causing serious arthralgia, deformity, dysfunction and kidney damage also often with or the illness such as complicated with diabetes, coronary heart disease, hypertension, obesity, blood fat disorder, can cause higher lethal disability rate, all, gout prevention is very urgent.
Tibetan medicine thinks, the wind-induced disease lineage of pain " grasserie " hyperuricemia being formed by metabolic arthritis is by " dragon " and the random a kind of disease causing of blood effect wadding, Tibetan medicine's " being directly " (meaning dirty onychonosus) by name.Because often eat the food rich in fat such as pungent, plump, excessive drinking, sitting is moving less, sit up night, tired undue, the internal injury of experiencing, the cause reasons such as fierce motion, incur blood function chaotic, in addition edible promote " dragon " partially food or the movement of Shengs appropriately incur that " dragon " is evil drives in the wrong direction, block blood samsara sering and excite.
The conventional Chinese patent medicine for the treatment of goat mainly contains at present: XINHUANGPIAN, Renshen Guipi Wan, Simiao San, JINGUI SHENQI WAN, gout stator, TONGFENGDING capsule etc., however, but the curative effect of these Chinese medicine preparation still can not be satisfactory.
There is tight demand in the Tibetan medicinal preparation that therefore, people better treat goat to curative effect.Up to now, also do not find the report of any relevant Tibetan medicinal composition of the present invention.The inventor, through research repeatedly, and by the checking repeatedly of a large amount of animals and clinical trial, has finally found the Tibetan medicine oral formulations of the treatment goat with better curative effect, thereby has completed the present invention.
Summary of the invention
The object of the invention is just to provide a kind of Tibetan medicine of more effectively treating goat and preparation method thereof.
Tibetan medicine of the present invention, be to be made or made by active component and pharmaceutically acceptable adjuvant by active component, wherein said active component is to be made by following bulk drugs: Artemisia sieversiana Willd., ZANGDANGSHEN, Mumiyah-asil, Radix Mirabilis himalaicae, Rhizoma Acori Calami.
It has selected Artemisia sieversiana Willd., ZANGDANGSHEN, Mumiyah-asil, Radix Mirabilis himalaicae, Rhizoma Acori Calami to combine as crude drug, and wherein (1) Artemisia sieversiana Willd. is the dry aerial parts of feverfew Artemisia sieversiana Willd. Artemisia sieversiana Willd. or Artemisia frigida Willd. Artemisia frigidaWilld..There is heat-clearing and toxic substances removing, loose swollen hemostasis, the effect of sharp kidney.For extremities joint swelling, carbuncle furuncle, sarcoma, pneumonopathy, nephropathy and spitting of blood, epistaxis.(2) ZANGDANGSHEN is the herb of the long flower of Campanulaceae Radix Codonopsis Codonopsis mollis Chipp..There is yellow fluid reducing, the effect of detumescence.For rheumatic arthritis, furuncle is bitterly swollen, leprosy.(3) Mumiyah-asil is that the feces of Lagomorpha Ochotonidae mammal ochotona erythrotis redeared pika Ochotona erythrotis Buchner forms through Preparation process; There is clearing stomach, liver, kidney-heat, Baconic, wooden cloth complication, the effect of the blood stasis dispelling that stimulates the menstrual flow; For digestive tract ulcer, with the passing of time hepatopathy, gout, menoxenia, puerperal abdonimal pain etc.(4) Radix Mirabilis himalaicae is the dry root of Nyctaginaceae plant Radix Mirabilis himalaicae Mirabilis himalaica (Edgew.) Heim..There is the kidney warming, granulation promoting, diuresis, calculus, the effect of dry " yellow fluid ".For cold syndrome of the stomach, renal cold, lower coldness of the body, sexual impotence edema, vesical calculus, lumbago, arthralgia, " yellow fluid " bitterly.(5) Rhizoma Acori Calami is aroid Rhizoma Acori Calami Acorus calamus L. and the dry rhizome that belongs to various plants together thereof.There is stomach warming, the effect of anti-inflammatory analgetic.Be used for mending stomach sun, dyspepsia, food is stagnant, diphtheria, the diseases such as anthrax.
Artemisia sieversiana Willd. has the effect of heat-clearing and toxic substances removing, loose swollen hemostasis, sharp kidney, principal agent in the side of being, be aided with ZANGDANGSHEN, Mumiyah-asil, Rhizoma Acori Calami activating qi and collateral, the dehumidifying of invigorating blood circulation of anti-inflammatory analgetic, expelling wind and removing dampness, yellow fluid reducing, be equipped with the kidney warming, granulation promoting, diuresis, calculus removing Radix Mirabilis himalaicae, jointly assist principal agent to bring into play better drug effect.These crude drug are used in combination and make each crude drug effect produce synergism, thereby can effectively treat goat.
The consumption of Tibetan medicine component of the present invention is also groped in a large number to sum up through inventor and is drawn, each crude drug consumption for all having good therapeutic effect within the scope of following concrete weight proportion:
Artemisia sieversiana Willd. 100～300g, ZANGDANGSHEN 75～225g, Mumiyah-asil 50～150g, Radix Mirabilis himalaicae 25～75g, Rhizoma Acori Calami 12.5～37.5g.
Can be preferably: Artemisia sieversiana Willd. 160～240g, ZANGDANGSHEN 120～180g, Mumiyah-asil 80～120g, Radix Mirabilis himalaicae 40～60g, Rhizoma Acori Calami 20～30g.
More preferably: Artemisia sieversiana Willd. 200g, ZANGDANGSHEN 150g, Mumiyah-asil 100g, Radix Mirabilis himalaicae 50g, Rhizoma Acori Calami 25g.
The preparation of Tibetan medicine active component of the present invention can be that the direct co-grinding of the crude drug of above-mentioned consumption is made; The conventional method that also crude drug of above-mentioned consumption can be adopted to Chinese medicine preparation makes as decoction and alcohol sedimentation technique or ethanol extract from water precipitation (referring to Cao Chunlin chief editor's < < pharmaceutics of Chinese drugs > > 73-74 page, Science and Technology of Shanghai publishing house publishes in November, 1986).
The active component of Tibetan medicine of the present invention can add various conventional adjuvant required while preparing different dosage form, if disintegrating agent, lubricant, binding agent etc. are with conventional method of Chinese medicinal (the < < pharmaceutics of Chinese drugs > > editing referring to Cao Chunlin, Science and Technology of Shanghai publishing house publishes in November, 1986) be prepared into any conventional peroral dosage form, as powder, pill, capsule, granule, tablet etc.
Tibetan medicine of the present invention has the function of anti-inflammatory analgetic.For gout, joint of the lower extremity congestion and swelling pain.
The usage and dosage of Tibetan medicine of the present invention is: oral; A 1～1.5g, 2～3 times on the one.
[specific embodiment]
Carry out by the following examples further to set forth the preparation method of Tibetan medicine of the present invention.
The preparation of [embodiment 1] Tibetan medicine powder of the present invention:
Take Artemisia sieversiana Willd. 200g, ZANGDANGSHEN 150g, Mumiyah-asil 100g, Radix Mirabilis himalaicae 50g, Rhizoma Acori Calami 25g, be jointly ground into fine powder after mixing, mix, subpackage, obtains powder.
The preparation of [embodiment 2] Tibetan medicine pill of the present invention:
Take Artemisia sieversiana Willd. 160g, ZANGDANGSHEN 120g, Mumiyah-asil 80g, Radix Mirabilis himalaicae 40g, Rhizoma Acori Calami 20g, after mixing, be jointly ground into fine powder, mix, with water pill, 60 ℃ of following being dried, polishing, packing, obtains pill.
The preparation of [embodiment 3] Tibetan medicine granule of the present invention:
Take Artemisia sieversiana Willd. 240g, ZANGDANGSHEN 180g, Mumiyah-asil 120g, Radix Mirabilis himalaicae 60g, Rhizoma Acori Calami 30g, after mixing, be jointly ground into fine powder, mix, add adjuvant granulation, 60 ℃ of following being dried, granulate, subpackage, obtains granule.
The preparation of [embodiment 4] Tibetan medicine capsule of the present invention:
Take Artemisia sieversiana Willd. 100g, ZANGDANGSHEN 75g, Mumiyah-asil 50g, Radix Mirabilis himalaicae 25g, Rhizoma Acori Calami 12.5g, be jointly ground into fine powder after mixing, mix, pack gelatine capsule into, packing, obtains capsule.
The preparation of [embodiment 5] Tibetan medicine tablet of the present invention:
Take Artemisia sieversiana Willd. 300g, ZANGDANGSHEN 225g, Mumiyah-asil 150g, Radix Mirabilis himalaicae 75g, Rhizoma Acori Calami 37.5g, after mixing, be jointly ground into fine powder, mix, add adjuvant granulation, 60 ℃ of following being dried, granulate, tabletting, subpackage, obtains tablet.
Tibetan medicine embodiment 1 powder of the present invention of take is below example, further sets forth the beneficial effect of Tibetan medicine of the present invention by test example, and these test examples have comprised pharmacodynamics test and the clinical observation on the therapeutic effect test of Tibetan medicine of the present invention.
[test example 1] Tibetan medicine of the present invention is to antalgic and inflammation relieving and fall the pharmacodynamics test of blood uric acid:
Test material: anthology invention Tibetan medicine embodiment 1 powder; Hypoxanthine is produced by Beijing Fine Chemical Works of cultivating people of ability, lot number 20090102; Aspirin is produced by Hunan Nan Guang pharmaceutcal corporation, Ltd, lot number 20090203; Probenecid is produced by integrated pharmaceutical factory, Shanghai, lot number 20090412; Glacial acetic acid is produced by Shanghai reagent four factories, lot number 090123; 210 of NIH mices, male and female half and half, body weight 18～22g, is provided by Qinghai Province's Experimental Animal Center.
Experimental technique and result: 1, pain model in mice, animal grouping and medication: get 50 of mices, be divided at random 5 groups, if model group, positive controls (aspirin 0.20g/Kg) and Tibetan medicine embodiment of the present invention 1 powder (0.75g/kg, 1.50g/kg, 3.00g/kg) low, in, high dose group, gastric infusion, 20ml/Kg, be administered once every day, continuous 2d, model group is to equivalent normal saline, after last administration, each Mus lumbar injection of 30min 0.6% glacial acetic acid 0.1ml/10g causes pain model in mice, observe and respectively organize incubation period and the interior writhing number of times of 30min that mouse writhing reaction occurs.The results are shown in Table 1.
Table 1 Tibetan medicine embodiment 1 powder of the present invention is on the impact of glacial acetic acid induced pain mice (x ± s, n=10)
Group number of animals dosage (g/kg) incubation period (min)
?writhing number of times (inferior/30min)
Model control group 10 3.58 ± 3.66 42.38 ± 22.36
Positive controls 10 0.20 4.37 ± 2.88 27.84 ± 8.46
Low dose group 10 0.75 3.23 ± 4.68 23.56 ± 6.48
*
Middle dosage group 10 1.50 9.13 ± 7.64
*13.24 ± 9.56
*
High dose group 10 3.00 12.46 ± 3.72
* *9.36 ± 8.14
* *
Illustrate: with model control group comparison:
*p<0.05;
*p<0.01;
* *p<0.001.
As seen from Table 1: in Tibetan medicine embodiment 1 powder of the present invention, dosage group can obviously extend the incubation period of glacial acetic acid induced pain mouse writhing reaction, low dose group all can reduce the number of times of writhing in 30min above, with model control group comparison, there is significant difference (P<0.05, P<0.01); And this effect of high dose group significantly (P<0.001).
2, mice auricle swelling model, animal grouping and medication: get 50 of mices, be divided at random model group, positive controls (aspirin 0.20g/Kg) and Tibetan medicine embodiment of the present invention 1 powder (0.75g/kg, 1.50g/kg, 3.00g/kg) low, in, high dose group, gastric infusion, 20ml/Kg, be administered once every day, continuous 5d, model group is to equivalent normal saline, after last medicine 1 hour, give every Mus auris dextra the wide 25 μ l Oleum Tigliis that are coated with, left ear compares, after 1 hour, put to death animal, cut ears, with 0.9cm standard card punch, lay the auricle of left and right ear same area.Analytical balance is weighed, and the difference of left and right ear weight is swelling.The results are shown in Table 2.
Table 2 Tibetan medicine embodiment 1 powder of the present invention causes the impact (x ± s, n=10) of mice auricle swelling on Oleum Tiglii
Group number of animals dosage (g/kg) ears weight differences (mg)
?suppression ratio (%)
Model control group 10 7.26 ± 1.38
Positive controls 10 0.20 6.49 ± 1.22 21.7
*
Low dose group 10 0.75 4.56 ± 0.66
△43.8
* *
Middle dosage group 10 1.50 5.21 ± 0.47 37.6
* *
High dose group 10 3.00 6.58 ± 0.62 20.8
* *
Illustrate: with model control group comparison:
*p<0.05;
*p<0.01;
* *p<0.001.With positive controls comparison:
△p<0.05.
As seen from Table 2: Tibetan medicine embodiment 1 powder of the present invention causes mice auricle swelling to Oleum Tiglii, has obvious inhibitory action.
3, mice pedal swelling model, animal grouping and medication: get 50 of mices, be divided at random model group, positive controls (aspirin 0.20g/Kg) and Tibetan medicine embodiment of the present invention 1 powder (0.75g/kg, 1.50g/kg, 3.00g/kg) low, in, high dose group, gastric infusion, 20ml/Kg, be administered once every day, continuous 4d, model group is to equivalent normal saline, after last medicine 1 hour, inject 100% Ovum Gallus domesticus album 20 μ l to every mice vola heart, after 1 hour, put to death animal, from ankle, accurately cut biped, torsion balance is weighed, the difference of biped weight is swelling (mg).The results are shown in Table 3.
Table 3 Tibetan medicine embodiment 1 powder of the present invention causes the impact (x ± s, n=10) of mice foot swelling on Ovum Gallus domesticus album
Group number of animals dosage (g/kg) swelling (mg)
?suppression ratio (%)
Model control group 10 96.5 ± 4.2
Positive controls 10 0.20 42.6 ± 5.3 34.8
*
Low dose group 10 0.75 44.7 ± 4.9 52.3
* △ △
Middle dosage group 10 1.50 51.3 ± 5.2 46.7
* △ △
High dose group 10 3.00 54.4 ± 5.1 45.3
Illustrate: with model control group comparison:
*p<0.01.With positive controls comparison:
△ △p<0.01.
As seen from Table 3: Tibetan medicine embodiment 1 powder of the present invention causes mice pedal swelling to Ovum Gallus domesticus album, has obvious inhibitory action.
4, antihyperuricemic disease mouse model, animal grouping and medication: get 60 of mices, be divided at random 6 groups, if blank group, model group, positive controls (probenecid 0.065g/Kg) and Tibetan medicine embodiment of the present invention 1 powder (0.75g/kg, 1.50g/kg, 3.00g/kg) low, in, high dose group, gastric infusion, 20ml/Kg, be administered once every day, continuous 4d, blank group, model group is to equivalent normal saline, after last administration 1h, except blank group, the equal Intraperitoneal injection of hypoxanthine 1g/Kg of all the other 5 treated animals makes antihyperuricemic disease mouse model, after injection hypoxanthine 30min, each treated animal is plucked eyeball and is got blood, the centrifugal 15min of 3000rpm, get serum and survey Level of Serum Uric Acid.The results are shown in Table 4.
The impact impact (x ± s, n=10) of table 4 Tibetan medicine embodiment 1 powder of the present invention on experimental hyperuricemia Mouse Blood uric acid level
Group number of animals dosage (g/kg) blood uric acid (μ mol/L)
Blank group 10 248.42 ± 121.44
* *
Model group 10 554.38 ± 127.46
Positive controls 10 0.065 429.24 ± 96.86
*
Low dose group 10 0.75 523.71 ± 67.78
Middle dosage group 10 1.50 483.46 ± 69.24
High dose group 10 3.00 432.14 ± 58.82
*
Illustrate: with model control group comparison:
*p<0.05;
*p<0.01;
* *p<0.001.
As seen from Table 4: Tibetan medicine embodiment 1 powder of the present invention can obviously reduce experimental hyperuricemia Mouse Blood uric acid level.
The clinical observation on the therapeutic effect of [test example 2] Tibetan medicine embodiment 1 powder treatment gout of the present invention:
Physical data: be in hospital and outpatient, totally 160 examples, are divided into two groups at random by digital method, treatment group 80 examples, male 76 examples, female's 4 examples, 30～64 years old age, average 45 years old; Disease time 3 days～8 years, average 1 year 06 months, onset 12 examples wherein, recurrence 68 examples, 58 examples were once taken expelling wind and removing dampness Chinese medicine or rheumatism, uricotelic drugs and effect is not good enough.Blood uric acid 423～645 μ mol/L before treatment, total white blood cells >10 * 10
9/ L 24 examples, ultrasound diagnosis companion urinary system calculus 19 examples, accompanied with hypertension 11 examples.Matched group 80 examples, male 77 examples, female's 3 examples, 31～65 years old age, average 46 years old, disease time 4 days～9 years, average 1 year 04 months, wherein onset 10 examples, recurred 70 examples, blood uric acid 426～630 μ mol/L, total white blood cells >10 * 10
9/ L 26 examples, ultrasound diagnosis companion urinary system calculus 16 examples, accompanied with hypertension 15 examples, two groups of clinical datas have comparability (P>0.05).
Diagnostic criteria: the diagnosis basis and the efficacy evaluation that mainly adopt " gout " in 1994 < < disease of tcm Standardization of diagnosis and curative effect > > of State Administration of Traditional Chinese Medicine issue.(1) mainly with single toe articulations digitorum manus, soldier is congestion and swelling pain so, and the acute as tiger of pain stings gradually, and very, repeatedly show effect light night in daytime.The diseases such as heat, headache of can occurring together.(2) be more common in aging male, can have gout family history.Often, because of fatigue, eating and drinking too much at one meal, eats high purine food, and drink and affection of exogenous wind-cold etc. brought out.(3) from the beginning of falling ill by simple joint, take the first metatarsophalangeal joints as common.Continue ankle, with, finger and other little joints, there is red and swollen heat pain, very articular cavity can sepage.Repeatedly after outbreak, can be with occurring between periarticular and auricle, helix and toe, phalanges " piece scrofula ' (tophus).(4) blood uric acid, the acid of urinating are increased.Stage of attack,, total white blood cells can increase.(5) make if desired kidney B ultrasonic and survey, routine urinalysis, the inspections such as renal function, to understand nephropathy situation after gout.X-ray is taken the photograph sheet inspection: the sclerotin that can show cartilage edge adjacent joints has irregular sample round defect of giving a farfetched interpretation.
Exclusion standard: (1) age <18 year or >70 year, trimester of pregnancy or women breast-feeding their children.(2) merge serious protopathy and the psychiatric patients such as cerebrovascular, cardiovascular companion severe cardiac, liver, renal insufficiency, or hemopoietic system.(3) late period, severe deformity in joint was stiff, disability person.(4) do not meet inclusive criteria, not medication in accordance with regulations, cannot judge that curative effect or data do not affect the treatment or safety judgement person entirely.
Therapeutic Method: 1, treatment group: adopt Tibetan medicine embodiment 1 powder of the present invention, 1.5g/ time, 1 day 3 times.
2, matched group: Allopurinol Tablets 0.1g/ time, every day 3 times is oral, sodium bicarbonate sheet 0.5g/ time, every day 3 times is oral, ibuprofen capsule 0.3g/ time, every day 2 times is oral.
All take for two groups and treat 30 days as 1 course for the treatment of, finish to add up therapeutic outcome 1 course for the treatment of, before and after treatment, all measure blood uric acid, adopt enzyme mark method.
Clinical efficacy evaluation criteria: the efficacy assessment standard of " gout " in 1994 < < disease of tcm Standardization of diagnosis and curative effect > > of employing State Administration of Traditional Chinese Medicine issue.
Cure: transference cure, lab testing is normal; Take a turn for the better: arthroncus is subdued, pain relief, lab testing is improved; Invalid: symptom and lab testing are unchanged.
Healing adding improvement and adding up to total effective rate.Clinical observation result is in Table 5,6.
Table 5 liang group patient clinical curative effect comparison (example, %)
Group clinical symptoms number of cases recovery from illness enabledisable total effective rate
Treatment group pain 80 60(75.00) 17(21.25) 3(3.75) 77(96.25)
Red and swollen 59 46(77.97) 10(16.95) 3(5.08) 56(94.92)
18 15(83.33 generate heat) 2(11.11) 1(5.56) 17(94.44)
Matched group pain 80 47(58.75) 21(26.25) 12(15.00) 68(85.00)
Red and swollen 57 36(63.16) 12(21.05) 9(15.79) 48(84.21)
19 15(78.94 generate heat) 2(10.53) 2(10.53) 17(89.47)
Note: two groups are compared P<0.05.
Blood uric acid comparison (x ± s) before and after table 6 liang group patient treatment
Blood uric acid (μ mol/L) after blood uric acid (μ mol/L) treatment before group treatment
Treatment group 522 ± 48 246 ± 63
Matched group 524 ± 56 251 ± 57
Note: before and after two groups of treatments, blood uric acid is P<0.05 relatively.
Untoward reaction: have no adverse reaction in treatment group therapeutic process; In matched group, having 6 examples to occur stomach discomfort, there is leukopenia in 3 examples, two groups of courses for the treatment of finishes rear check hepatic and renal function all normal.
Clinical observation result shows: two groups of patients apply after above Drug therapy, and blood uric acid obviously declines, and the clinical symptoms such as arthralgia, redness obviously alleviate or disappear.Illustrate that Tibetan medicine embodiment 1 powder of the present invention has good therapeutical effect, pain, redness, heating etc. improve aspect, total effective rate, blood uric acid descending water and are on average better than matched group, and Tibetan medicine embodiment 1 powder of the present invention has certain application prospect.
In the preparation of conventional oral solid formulation dosage form, the preparation of powder belongs to part operation above in other conventional oral solid formulation preparation process, the test example of powder has proved having good effect aspect treatment goat, has also just illustrated that pill, granule, capsule, the tablet in conventional oral solid formulation dosage form also has same effect; Be that the above-mentioned embodiment enumerating 1-5 has same effect.Illustrate that Tibetan medicine of the present invention has good effect aspect treatment goat.
Claims (5)
1. a Tibetan medicine for the treatment of goat, it is characterized in that it is to be made or made by active component and pharmaceutically acceptable adjuvant by active component, wherein said active component is to be made by the crude drug of following concrete weight proportion: Artemisia sieversiana Willd. 100～300g, ZANGDANGSHEN 75～225g, Mumiyah-asil 50～150g, Radix Mirabilis himalaicae 25～75g, Rhizoma Acori Calami 12.5～37.5g.
2. Tibetan medicine according to claim 1, wherein said active component is to be made by the crude drug of following concrete weight proportion: Artemisia sieversiana Willd. 160～240g, ZANGDANGSHEN 120～180g, Mumiyah-asil 80～120g, Radix Mirabilis himalaicae 40～60g, Rhizoma Acori Calami 20～30g.
3. Tibetan medicine according to claim 2, wherein said active component is to be made by the crude drug of following concrete weight: ZANGDANGSHEN 150g, Mumiyah-asil 100g, Artemisia sieversiana Willd. 200g, Radix Mirabilis himalaicae 50g, Rhizoma Acori Calami 25g.
4. according to any one Tibetan medicine described in claim 1-3, it is peroral dosage form.
5. Tibetan medicine according to claim 4, it is powder, pill, granule, capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410131046.7A CN103933277A (en) | 2014-04-03 | 2014-04-03 | Tibetan drug for treating gout disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410131046.7A CN103933277A (en) | 2014-04-03 | 2014-04-03 | Tibetan drug for treating gout disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103933277A true CN103933277A (en) | 2014-07-23 |
Family
ID=51181334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410131046.7A Pending CN103933277A (en) | 2014-04-03 | 2014-04-03 | Tibetan drug for treating gout disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103933277A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113827651A (en) * | 2021-11-16 | 2021-12-24 | 西藏大学 | Tibetan radix codonopsis compound composition with anti-allergy and relieving effects and preparation method and application thereof |
| CN115350227A (en) * | 2022-09-22 | 2022-11-18 | 赵奎 | Traditional Chinese medicine composition for treating gout and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813861A (en) * | 2005-11-29 | 2006-08-09 | 久美彭措 | Five-ingredient medicinal-bathing particle |
| CN102441081A (en) * | 2011-11-21 | 2012-05-09 | 宋永心 | Medicament for treating gout and its preparation method |
-
2014
- 2014-04-03 CN CN201410131046.7A patent/CN103933277A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813861A (en) * | 2005-11-29 | 2006-08-09 | 久美彭措 | Five-ingredient medicinal-bathing particle |
| CN102441081A (en) * | 2011-11-21 | 2012-05-09 | 宋永心 | Medicament for treating gout and its preparation method |
Non-Patent Citations (3)
| Title |
|---|
| 仁青措: "浅谈藏医直合乃的治疗方法", 《中国民族医药杂志》 * |
| 刘忠等: "藏药七味罗堆多吉颗粒剂镇痛、抗炎作用的实验研究", 《江苏中医药》 * |
| 尕日毛: "藏药桑当聂莪治疗类风湿关节炎210例", 《中国民族医药杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113827651A (en) * | 2021-11-16 | 2021-12-24 | 西藏大学 | Tibetan radix codonopsis compound composition with anti-allergy and relieving effects and preparation method and application thereof |
| CN113827651B (en) * | 2021-11-16 | 2022-03-25 | 西藏大学 | Tibetan radix codonopsis compound composition with anti-allergy and relieving effects and preparation method and application thereof |
| CN115350227A (en) * | 2022-09-22 | 2022-11-18 | 赵奎 | Traditional Chinese medicine composition for treating gout and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102441081B (en) | Medicament for treating gout and its preparation method | |
| CN100531769C (en) | Chinese medicine composition for treating gout and preparing method thereof | |
| CN103393827B (en) | Medicinal liquor for treatment of gout | |
| CN100355450C (en) | Qinchuan Tongbi tablet | |
| CN100536886C (en) | External-applied traditional Chinese medicine composition for treating gout | |
| CN101703684B (en) | Medicament for treating allergic purpura and preparation method thereof | |
| CN103169883B (en) | Traditional Chinese medicine for treating infantile jaundice | |
| CN101745047A (en) | Chinese medicinal composition for treating gout disease and preparation method thereof | |
| CN106039109A (en) | Traditional Chinese medicinal liquor for preventing and treating cold dampness accumulation pattern rheumatoid arthritis | |
| CN103933277A (en) | Tibetan drug for treating gout disease | |
| CN102240351B (en) | Traditional Chinese medicine for treating Arthritis, hyperosteogeny, cervical disc herniation and cervical spondylosis | |
| CN104069355A (en) | Medicinal composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN104208369B (en) | Five-stem ease pill for treating gout | |
| CN103405653A (en) | External preparation for treating gouty arthritis | |
| CN102846750B (en) | Fengtongning composite preparation and preparation method thereof | |
| CN103933278A (en) | Preparation method of Tibetan drug for treating gout disease | |
| CN105362798A (en) | Traditional Chinese medicine for treating gouty arthritis and preparation method of traditional Chinese medicine | |
| CN101912570B (en) | Medicinal composition for treating rheumatism and preparation method thereof | |
| CN1943766A (en) | A Chinese traditional medicinal preparation for treatment of psoriasis | |
| CN102335304B (en) | Chinese medicine composition for dispelling wind, removing dampness, invigorating blood circulation, and relieving pain and preparation method thereof | |
| CN103893732B (en) | A kind of Tibetan medicine treating chronic gastritis | |
| CN103099861B (en) | Six rattans are drunk in treatment rheumatoid arthritis | |
| CN107510765A (en) | A kind of Chinese medicine composition for treating phlegm-blood stasis numbness network type rheumatic Bi syndrome and preparation method thereof | |
| CN107281416A (en) | A kind of preparation that urarthritis is treated containing long-nosed pit viper | |
| CN101129501A (en) | Externally used medicinal wine for curing gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140723 |
|
| RJ01 | Rejection of invention patent application after publication |